Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Illumina, Inc.    ILMN

ILLUMINA, INC.

(ILMN)
  Report
Delayed Quote. Delayed Nasdaq - 10/22 04:00:00 pm
325.92 USD   +2.54%
10/07ILLUMINA, INC. : Report
CO
10/05ILLUMINA, INC. : Report
CO
10/01ILLUMINA, INC. : Report
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Illumina to buy Jeff Bezos-backed cancer testing firm Grail in £6.23 billion deal

share with twitter share with LinkedIn share with facebook
09/21/2020 | 12:23pm EDT
FILE PHOTO: A new office building housing genetic research company Illumina is shown in San Diego, California

Illumina Inc said on Monday it would buy cancer screening startup Grail Inc in a cash-and-stock deal worth $8 billion (£6.23 billion), buying out investors including Jeff Bezos and snatching back a business it spun out four years ago.

Grail is developing a liquid biopsy, a blood test intended to diagnose cancers at early stages when the disease is easier to treat. The company has said it expects to launch its flagship test Galleri in 2021, betting on a market expected to grow rapidly in coming years.

Grail was founded by Illumina as a separate company in 2016 and had since raised about $2 billion, with investors including the founders of Amazon.com Inc and Microsoft. Illumina remained its largest shareholder, owning about 14.5% of its outstanding shares. Illumina Chief Executive Francis deSouza said in an interview that he began speaking to his board early this year about acquiring Grail after the start-up released promising data on its experimental diagnostic. "From our perspective, early detection of cancer is the largest application of genomics for the next decade, decade and a half," he said. Many cancers, like ovarian cancer, are difficult to diagnose and often only caught when the disease has spread to other areas of the body, when it is far deadlier. If a blood test can effectively detect these cancers earlier, it could significantly improve the prognosis for many patients.

Analysts have forecast a future market for liquid biopsies as high as $130 billion in the United States alone.However, the technology is still experimental and must demonstrate efficacy in clinical trials before being approved by regulators.

Illumina shares fell 8.3% to $271.07, as some analysts questioned the deal's rationale.

"We don't see the clear fit for acquiring a company that is still at a stage where clinical studies and clinical product development are still critical and will be for years," Cowen analyst Doug Schenkel said in a research note.DeSouza attributed the stock reaction to the deal's cost. "It's just a big deal. The numbers are large and so investors want to process what this means," he said. DeSouza said the deal fits into Illumina's long-term strategy of developing next generation technology that uses human genetics to improve patients' lives.

By Manojna Maddipatla and Rebecca Spalding


Stocks mentioned in the article
ChangeLast1st jan.
AMAZON.COM, INC. -0.27% 3176.4 Delayed Quote.71.90%
ILLUMINA, INC. 2.54% 325.92 Delayed Quote.-1.75%
MICROSOFT CORPORATION 0.04% 214.89 Delayed Quote.36.27%
share with twitter share with LinkedIn share with facebook
All news about ILLUMINA, INC.
10/07ILLUMINA, INC. : Report
CO
10/05ILLUMINA, INC. : Report
CO
10/01ILLUMINA, INC. : Report
CO
09/28ILLUMINA : to Announce Third Quarter 2020 Financial Results on Thursday, October..
BU
09/25JOHNSON & JOHNSON, NIKE, ILLUMINA : Stocks That Defined the Week
DJ
09/23ILLUMINA : to Webcast Upcoming Investor Conference Presentation
BU
09/21Nikola, Illumina fall; Cubic, Rent-A-Center rise
AQ
09/21Nikola, Illumina fall; Cubic, Rent-A-Center rise
AQ
09/21Illumina to buy Jeff Bezos-backed cancer testing firm Grail in £6.23 billion ..
RE
09/21JEFF BEZOS : Illumina to buy Jeff Bezos-backed cancer testing firm Grail in $8 b..
RE
More news
Financials (USD)
Sales 2020 3 095 M - -
Net income 2020 550 M - -
Net cash 2020 2 068 M - -
P/E ratio 2020 86,4x
Yield 2020 -
Capitalization 47 702 M 47 702 M -
EV / Sales 2020 14,7x
EV / Sales 2021 11,8x
Nbr of Employees 7 700
Free-Float 75,1%
Chart ILLUMINA, INC.
Duration : Period :
Illumina, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ILLUMINA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Average target price 297,25 $
Last Close Price 317,85 $
Spread / Highest target 19,6%
Spread / Average Target -6,48%
Spread / Lowest Target -30,8%
EPS Revisions
Managers
NameTitle
Francis A. deSouza President, Chief Executive Officer & Director
Jay T. Flatley Executive Chairman
Robert P. Ragusa Senior Vice President-Global Quality & Operations
Sam A. Samad Chief Financial Officer & Senior Vice President
Phillip G. Febbo Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ILLUMINA, INC.-4.19%46 521
THERMO FISHER SCIENTIFIC44.29%185 436
DANAHER CORPORATION47.61%160 717
INTUITIVE SURGICAL, INC.23.23%85 637
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.101.00%67 008
BOSTON SCIENTIFIC CORPORATION-17.85%53 150